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Introduction 
Science and Technology Parks (or S&T parks) are an “in ovation in public 
investment” borrowed from the U.S.A. where they first emerged in the University of 
Stanford in 1951 and evolved to become the famous “silicon valley” phenomenon. 
During the 1980’s they became increasingly popular in Europe as well as developing 
countries, as a means for the State to support entrepreneurs and innovation creation. 
S&T parks permit the sharing of scare resources such as quality infrastructure (land, 
buildings, electricity, water, and communications), provide links to research 
institutions, give business support, and incubate start-ups, especially from public 
laboratories. Currently, there are “hundreds possibly even thousands of parks housing 
technology related activities” in India, according to a report of The Allen Consulting 
Group (2005). Most of them are supposedly, State sponsored (either by the Central 
Government or the State Government), though there are p rks which have been 
created by private investors. In any developing country, with resource constraints, it is 
doubly obviously to ensure the rationality of investment. Most of the existing 
literature in economics seems to assume that such a condition is always satisfied and 
go on to focus on two important questions that are pertinent in the post-investment 
period: how can the performance of an S&T park be evaluated? What are the set of 
“best practises” that can be replicated?  However, it is widely acknowledged that the 
rates of return from S&T parks in many developing countries are far below the 
expected mark, which calls for the development of better “indicators” for policy 
makers to make investment decisions on the location and composition of S&T parks 
in the first place. With respect to the above problem, the present paper attempts to 
develop one such tool in the form of indicators based on scientific publications and 
patents to be used for making investment decisions about S&T parks. It then 
illustrates them with the case study of investment in S&T parks in the state of Gujarat 
in India.  
 
The rationality of the spawning of S&T parks in emerging economies is quite clear. 
Hi-Tech sectors refer to science based industries wth ell defined niches that require 
the participation of highly qualified scientists and where the technology embodied in 
the final product or process is changing rapidly (say between 2 to 6 years) leading to 
new products, improved quality or a lower cost of production. They include sectors 
such as pharmaceuticals, crop seeds, microelectronis, new materials, and information 
and communications technology. These are widely recognized as being crucial thrust 
areas for employment and revenue generation. 
 
Though no “sufficient conditions” have been identified for the creation of industrial 
competence in new science based sectors, a set of necessary conditions for any 
developing country to catch-up in the high-tech sectors seems evident (Jolly and 
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Ramani, 1996). First, there has to be an adequate bas  of skilled scientific labour. This 
means that the university and public research laboratories have to ensure the supply of 
a sufficient quantity and quality of scientists, who are up to date in the required 
scientific fields. Second, there has to be an adequat  circulation of resources 
(information, labour, people and capital) between the research market where public 
laboratories are most active, the technology markets wi h both firms and public 
laboratories and the final product markets formed of manufacturing firms. Third, there 
must be sufficient incentives for the transformation of research output into product or 
process innovations. Any costly R&D investment, whose returns are uncertain, will be 
undertaken only if the expected profit is sufficiently high. Expected profit is 
determined by a number of technological, firm and market features such as: 
possibilities for imitation, firm-specific competence, production capacity, market 
share, market competition, ownership of required an complementary assets, level of 
entry barriers and macro factors such as government subventions, government 
regulations, intellectual property rights, functioning of financial markets etc. The sum 
result of the interaction between these parameters mu t be so as to result in a high 
enough expected profit to make R&D investment worthwhile. Fourth, there must be 
agents in the economy (the government, the public, the firms or the capital markets) 
who are willing to bear the risk of innovation creation. R&D and targeted innovation 
efforts are distinguished from other activities such as manufacturing or marketing, in 
that they are essentially “search” activities whose utput is uncertain and which are 
not amenable to the application of an “efficiency criterion”. Therefore, sectors 
characterized by intense R&D activity will not grow unless there are firms with big 
pockets or the firms group together to share the risk, or other agents such as venture 
capitalists, the public, or the government share the risk with innovating firms. 
 
Governments in emerging economies have been able to satisfy the first necessary 
condition through investment in the creation of qualified personnel through 
investment in public education and to some extent the last condition through the 
creation of public venture capital companies, but they are finding it more difficult to 
satisfy the second and third condition as they requi  the mobilisation of a variety of 
agents, changes in the business environment and in market beliefs about the potential 
for rent appropriation from innovation. In addition, given the paucity of resources to 
which all emerging economies are subject to, it is even more imperative to maximise 
the economic returns from existing investment in public research through the creation 
of institutions and conventions that promote the transfer of knowledge from public 
laboratories to private firms and aid in its transformation into commercializable 
technology (Ramani, 2002). S&T parks provide one such convention to promote the 
satisfaction of the second and third necessary conditi s for developing competence 
in a new science based sector. 
 
How should any country decide where to invest in a science and technology park and 
who should be permitted to be a member in the Park? There can be many criteria for 
this choice and many tools according to which such criteria can be measured. In this 
paper, we do not present the criteria that are necessary or sufficient for a zone to be 
chosen for investment in a park or for the entry of a firm or a laboratory in such a 
park. Instead, we explore how data on scientific publications and patents, with all 
their drawbacks can be used as indicators for investm nt in Science and Technology 




This paper is organized in four sections. The firstsection, gives an overall description 
of Science Parks in India with particular focus on the actual investments that have 
been made in Gujarat. The second section examines how scientific publications and 
patents can be used as indicators for investment. The third section analyzes the data 
on scientific publications and patents, with respect to India as a whole as well as the 
State of Gujarat. The fourth and final section tries to draw inferences for policy and 
concludes. 
 
Setting the background on India and Gujarat2  
Richk, Petkov and Spiro (1999) present the definitio  of a science and technology 
(S&T) park that is useful as it clearly identifies it unique features3.  According to 
them, a science park “is a property-based initiative, which has formal and operational 
links with universities or other higher educational institution, or major centers of 
research; is designed to encourage the formation and growth of knowledge-based 
industries or high value-added firms, normally resid nt on site; and has a steady 
management team actively engaged in fostering the transfer of technology and 
business skills to tenant organizations”.  
 
S&T parks were introduced in India under the aegis of the STEP program or The 
“Science and Technology Entrepreneurs Park” program instituted by the government 
in 1984. Initially there were located in universities and were to aid the development of 
qualified S&T labour and to integrate them in entrepreneurial industrial development. 
Today, however, there is a great heterogeneity among the parks; some are just a single 
building while others are spread over sprawling campuses. Some are very focussed, 
either on biotechnology or informatics or exports, while others house a variety of 
tenants. Out of these thousands, only those located in the following cities (or the 
adjacent suburbs of these cities) have made a mark: New Delhi, Hyderabad, 
Bangalore, Chennai and Trivandrum. Barring New Delhi, which is the capital of 
India, all others are located in the cities of the Southern cities, reflecting a southern 
cluster. Four industrial sectors stand out as having benefited from the S&T parks: soft 
ware, bio-informatics, Information and communications technology (ICT) and 
biotechnology (Allen Consulting Group, 2005).  
 
Gujarat emerged as a state of India in 1960 and at that time it was largely an agrarian 
economy with an insignificant industrial base. Today it is the second most 
industrialized state (the first being Maharashtra) in India with a per-capita GDP 
significantly above the national average. This is in part attributed to its cultural 
heritage. The Gujaratis, as the natives of Gujarat e called, are famed in Indian 
history, for their entrepreneurial skills. With resp ct to the whole of India, the state 
accounts for 11% of industrial production, 8.5% of industrial employment and 9.7% 
of industrial units. With 4.88% of the country’s population, the state contributes to 
11% of India’s GNP. Being located on the Western coast f India, Gujarat also boasts 
of the longest coastline (about 1600 kms) in the country, which lends it a rich marine 
biodiversity. 
 
                                               
2 The figures on Gujarat cited in this section are drawn from the internet sources given in the 
references. 
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1.1.1. The pharmaceutical sector of Gujarat  
Among the knowledge intensive sectors, Gujarat is be t known for its strength in 
pharmaceuticals though it also has a strong base in chemical, textile, food processing 
industries. The pharmaceutical firms in Gujarat supply cater to 45% of the total 
demand in the country. For many years Gujarat has been leading in the 
pharmaceutical sector. However in recent times, there has been a worry that the 
industry is on the verge of losing out its premier position to other industrially up-
coming states like Karnataka and Andhra Pradesh. The pharma lobby in Gujarat has 
been quick to point fingers at the unfocussed industrial policies of the successive state 
governments. The most prominent firms in the pharmaceutical sector are listed below. 
 
1.1.2. The academic-public lab network in Gujarat 
Gujarat has 13 universities and 4 agricultural universities (out of which Gujarat 
Agricultural University is one of the largest in Asia). Among the universities, six offer 
post-graduate biotech and related courses: M. S. University of Baroda (Vadodara), 
Sardar Patel University (Vallabh Vidyanagar), Saurastra University (Rajkot), South 
Gujarat University (Surat), Hemchandracharya North Gujarat University ( Patan, 
North Gujarat) and Gujarat University, Ahmedabad 
  
There are two prominent national laboratories working on biotech related areas.  
The CSIR4-run Central Salt and Marine Chemicals Research Institute 
(CSMCRI) in Bhavnagar is the anchor for the biotech research activities in 
Gujarat5. The state is keen to develop expertise in marine b otechnology in a big 
way with CSMCRI’s help. It is discussing with the institute to set up an institute 
for excellence in marine biotechnology. The Gujarat government has also roped in 
CSMCRI to initiate environment biotechnology programmes. 
 
The National Dairy Development Board (NDDB), the world’s largest dairy 
development program, based in Anand near Vadodara, is carrying out extensive 
research and development activities in biotechnology. It aims to develop 
formulations and technologies useful for improving the productivity of mulch 
animals.  
 
Interviews with some key faculty at the M. S. University, Baroda as well as with some 
captains of the pharmaceutical industry revealed that e following problems are 
being tackled by the public institutions of research (Coronini, Ramani, Venkatesh 
(2004)).  
 
Low research productivity at the level of the lab: Apart from the M. S. University, 
other institutions have not made a significant mark in the international research arena. 
Quality research is largely because of foreign collaborations, where the foreign 
collaborator provides the funds. To date there has been more hype associated with 
biotechnology and basic issues such as space and budget allocations have not been 
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marine algae, photo-inorganic chemistry and phyto-salinity 
 5 
dealt with. There is always a resource crunch and even maintenance budgets are 
abysmally low.  
 
A teaching curriculum with poles of excellence but without standardization: The 
biotechnology course syllabus is being constantly revised and kept up to date at the 
Masters level. In the M. S. University, for instance, starting this year, apart f om the 
regular course, another masters programme has been initiated to meet the needs of 
industry. However, many institutes have started to offer under-graduate courses in 
biotechnology, as part of a bandwagon effect, and it is doubtful whether such courses 
are of any value. 
 
Lack of teachers, lack of good leaders, lack of incentives: Faculty members are in 
short supply even in reputed institutions like the M. S. University. It has been seen 
that over the years even filling up of posts where faculty have retired has not 
happened, leave alone creating new faculty position. To keep an institution vibrant, it 
is necessary to ensure that faculty positions are replenished periodically. Quite often 
academic institutions have poor leadership who do not understand the needs of 
academia. Archaic rules and regulations also become a constraint in delivering the 
goods.  
 
Graduates with better practical and communication skills needed: The pharma 
industry needs pharma graduates and postgraduates with good technical skills (like 
immunoblotting, protein/genome analysis, western blotting etc), good understanding 
and reasoning capabilities and good communication skills. Students come armed with 
theoretical knowledge, but little practical knowledg  or awareness of industry and 
poor communication skills.  
 
1.1.3. Government Initiatives 
The State Government had set up the State Biotechnology Mission (GSBTM) in 2003 
to facilitate the development of biotechnology in the state. It is under the 
administrative control of the Department of Science and Technology. This has been 
created to catalyse the development of the Gujarat Biotech sector through feasibility 
studies, organization of fairs and exhibitions, organization of seminars and 
conferences, training etc. The achievements of this mi sion are not clear at the 
moment.  
 
In 2004, when we studied the Gujarat biotech landscape, there were a number of 
promises made on the good things to come6.  
• New R&D centres: to apply industrial biotechnology knowledge into 
industrial application and commercial products.  
• Establishment of an Institute of Bioinformatics in Gujarat. 
• Setting up of “The Gujarat Biotechnology Venture Fund (GBVF)”, a 
12-year close-ended Venture Capital Fund with an initial proposed 
fund of Rs. 500 million involving both Government and corporate 
funding. 
                                               
6 Again we are in the process of examining which of these promises came true and to what extent. 
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• Updated version of the plans for infrastructure development in a 
document called Blueprint for Infrastructure Development 2020 (BIG 
2020). 
 
2. Indicators for investment in S&T Parks 
2.1. Compilation of data base  
The data on scientific publications was extracted from the database Science Citation 
Index Expanded™, which is available through the Web of Science®. Two groups of 5 
corpuses of information were compiled for the scientific publications. The first five 
groups were publications stemming from India:  
 
• Exclusively dealing with health and stemming from India as a geographical 
region7.  
• Exclusively dealing with agriculture and stemming from India as a 
geographical region8.  
• Exclusively dealing with biotechnology and stemming from India as a 
geographical region9.  
• Dealing with both biotechnology and health10.  
• Dealing with both biotechnology and Agriculture11. 
 
From the above corpus of information compiled, we extracted four sub-corpuses of 
information as related to 5 fields: pure pharmaceuti als, pure agriculture, pure 
biotechnology, biopharma (pharma and biotech) and agbiotech (agriculture and 
biotech) as given in figure 1. Then following the same method, we obtained five sets 
of scientific publications corresponding to the same fields and produced by scientists 
from Gujarat.  
 
To compile the corpus on patents, two databases available on CD Roms were used, the 
USPTO (US Patent Office) and EPO (European Patent Office)12. The two patent office 
databases USPTO and EPO yielded two different images of patent depositions from 
India. In the EPO, India was indentified by the field “PR number” or the priority 
number of the country with the two letters IN. In order to identify Indian patents in the 
USPTO, the only indicator was the country of the inve tor INCO in which the letters 
IN implied a patent from India. All patents with at least 1 inventor from India were 
considered. Then all the common fields of the USPTO and EPO were recorded.  
 
                                               
7The research equation used was ((TS=PHARMA* OR TS=DRUG OR TS=DRUGS OR 
TS=MEDICINE* OR TS=MEDICATION)OR TS=HEALTH) OR (TS=DIAGNOSTIC* AND 
TS=HEALTH)) AND AD=INDIA. 
8 The research equation used was (TS=AGRO* OR TS=AGRI*) AND AD=INDIA. 
9 The research equation used was ((TS=BIOTECH* OR TS=BIO-TECH* OR TS=NANOBIOTECH* 
OR TS=NANO-BIOTECH*) OR (TS=BIOLOG* SAME TS=MOLECU*)) AND AD=INDIA. 
10 Add first and third equations. 
11Add second and third equations. 
12 (AB = "pharma*" OU AF="pharma*"OU ET="pharma*" OU FT="pharma*" OU AB = "medic*" 
OU AF="medic*"OU ET="medic*" OU FT="medic*" OU AB = "drug*" OU ET="drug*" OU 
AB = "bio*" OU AF="bio*"OU ET="bio*" OU FT="bio*" OU AB = "health*" OU 
AF="sante*"OU ET="health*" OU FT="sante*") AVEC (PR="IN*") ETSAUF NO=* 
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2.2. Indicators used 
DeLooze and Ramani (2002) discuss the uses and misuses of patent statistics as 
indicators of technological competence. They present a variety of indicators that 
represent competitive position and comparative advantage of agents (firms, labs, 
regions, individuals) in a technology. In what follows, we shall be using four of these 
indicators to analyze investment strategies. We present the four indicators for 
publications. By replacing patents in the place of publications the same can be derived 
for patents. 
 
1. Internal Structure of knowledge base 
Any agent can invest in creating knowledge in a variety of subjects or technology 
fields. The internal structure of knowledge base thn reveals the ordering of 
competencies acquired in the different fields, thus giving insight on the priority fields 
earmarked by the agent.  
 
Relative importance of region or lab j in field k = 
 
number of publications of region/lab j in field k
.100







2. Competitive index of region or lab  j in field k 
Regions compete with each other to create knowledge. Th  competitive index in a 
particular field measures the leadership position or the ranking of a region vis-à-vis 
the country in that particular field.  
 
Competitive index of region or lab j in field k = 
 
number of publications of region/lab j in field k
.100







3. Global competitive index of region or lab  j  
Similarly the Global competitive index is a measure of the over-all differences 
between agents. It can be regarded as an indicator of he “weight” of the knowledge 
base. But a best over-all ranking does not necessarily imply a competitive advantage, 
as an agent which is not ranked well in the overall global competitive index might 
have a very good position in a particular strategic technology. 
 
Global competitive index of region or lab j = 
 
number of publications of region/lab j in all fields
.100






4. Comparative advantage (CA)  of region or lab  j in field k 
This basically stems from the Ricardian notion that tr de is beneficial if the trading 
countries specialise in their fields of comparative advantage. Areas of comparative 
advantage refer to fields in which the difference in the efficiency of production of the 
agent concerned vis-à-vis the other agent or agents is the maximum. This gives an 
indicator for short-term investment, exhorting regions to invest and develop 
maximum efficiency in areas of their comparative advantage. On the other hand, 
many studies have pointed out that blind application of this principle is risky in the 
long run because of over-concentration of investmen on a few sectors or regions that 
are already the best in an ever-changing environment. Therefore, for long term even 
development it is also necessary to invest in areas of comparative disadvantage in the 
long run.  
 
Comparative advantage of region or lab j in field k = 
 
competitive index of region/lab j in field k






The comparative advantage index is adapted from the Revealed Technology 
Advantage Index (RTA index) constructed by Pavitt and Patel, (1988). A country is 
said to have a CA in a field if its CA index is great r than 1 in that field, otherwise 
not. The intuition is clear, according to the above formula, the denominator indicates 
the average competitive position of a region. If in a y particular sector, the 
competitive position of the region is higher than on average then it has a comparative 
advantage in the area. The CA index specifies the areas of nation-specific advantage, 
in which a country is encouraged to invest more in the short run. 
 
3. Applications to India and Gujarat 
 
3.1 Publications: India, Gujarat and the rest of the world 
Let us first start with an evolution of the scientific publications in the five fields under 
consideration: pure pharma, pure agriculture, biotechnology, biopharma and 
agbiotech. The evolution of publications in the world and in India are represented in 
the following two tables. It is to be noted that for the year 2004 the data is not 
complete. In what follows, the category “agro” refers to publications that are related 
to agriculture but without any biotech component and similarly for “pharma”. The 
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“agbiotech” and “biopharma” fields then represent the integration of biotech in the 
corresponding fields.  The “biotech” category gives the number of publications related 
to biotechnology that are unrelated to pharmaceuticals or agriculture. It could be pure 
biotechnology or applications to other industrial sectors. The total number of 
publications in each category was considered as the world production. Then the 
number of publications from India were identified and these figures were subtracted 
from the world production to compare production from India vis-à-vis the rest of the 
world 
 
Table 1  
Evolution of publications from India 
 
 Agro Pharma Biotech Agbio Biopharma 
1994 140 415 29 1 2 
1995 149 484 28 3 9 
1996 154 519 39 4 5 
1997 140 550 40 3 4 
1998 188 678 46 4 9 
1999 201 735 42 8 12 
2000 225 755 51 12 16 
2001 251 912 39 14 19 
2002 254 1102 55 9 19 
2003 320 1314 65 8 25 
2004 241 1101 46 7 18 
Total 2263 8565 480 73 138 
      
Average 
rate of 
growth 10,29 13,90 11,31 40,17 58,62 
 
The above table clearly indicates that the mass of Indian science production is 
concentrated in pharmaceuticals. Furthermore, a computation of the average rate of 
growth13 reveals that knowledge related to biopharmaceuticals s growing the fastest, 
followed by agbiotech, indicating that these are th“thrust areas” of growth in 
scientific knowledge India. 
 
                                               
13 First the average rate of growth per year was computed for the 9 years: 1995-2003. The year 2004 
was not considered since data is incomplete. Then an average was computed over these 9 figures for 
rates of growth. 
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Table 2 
Evolution of publications in the rest of the world 
 
  Agro  Pharma Biotech Agbiotech Biopharma 
1994 3693,00 43613,00 1928,00 73,00 336,00 
1995 3877,00 46613,00 2342,00 60,00 373,00 
1996 4077,00 50591,00 2525,00 86,00 451,00 
1997 4385,00 54132,00 2613,00 101,00 481,00 
1998 4697,00 59429,00 2822,00 106,00 521,00 
1999 4864,00 62262,00 3024,00 114,00 525,00 
2000 5265,00 63587,00 3065,00 145,00 634,00 
2001 5229,00 66616,00 3173,00 151,00 626,00 
2002 5732,00 69081,00 3135,00 134,00 699,00 
2003 6792,00 80942,00 3480,00 168,00 821,00 
2004 4957,00 62616,00 2616,00 116,00 610,00 
Total 53568,00 659482,00 30723,00 1254,00 6077,00 
      
Average rate of growth 7,12 7,19 6,96 11,21 10,70 
 
Comparing India, with the rest of the world, we can see that they share a number of 
common features. The common feature is that the mass of publications both 
worldwide and from India are concentrated in pharmaceuticals. In both regions, the 
number of publications in pharmaceuticals is almost or greater than four times that in 
agriculture and more than ten times that in biotechnology. However, the difference in 
the growth rates of  the biotech segments and the pur agriculture and pure pharma 
segments are much less at the world level. Finally, it is interesting that the rate of 
growth of science in all biotech realted fields in India, is greater than the rest of the 
world average, which means that there is a possibility to achieve a leadership position 
in the same.  
 
As far as Gujarat is concerned, in the SCI database, there are 6553 publications in all 
fields emanating from Gujarat. Out of this 238 are in pure pharma, 79 in pure agro, 11 
articles in biotech (not related to agriculture or pharmaceuticals) and 1 in agbiotech 
and 1 in biopharma. 
 
Applying the simple indicators given earlier to theabove data we can derive the 
following result.  
 
Result 1:  
• To maximize returns from science production, in the s ort run, India should 
invest in agbiotech, pure agriculture and biotechnology (in decreasing order), 
and to ensure high returns in the long run it should invest in  pure pharma. 
 
• To maximize returns from science production, in the s ort run, Gujarat should 
invest in pure agriculture. To ensure high returns i  the long run, Gujarat 
should invest in pharmaceuticals, biotechnology,  agbiotech and biopharma 
(in decreasing order).   
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These results can be easily derived by constructing a portrait of India’s investment 
and Gujarat’s investment as follows. 
 
Table 3 
















Agro 7,13 19,65 4,22 2,75 
Pharma 87,80 74,36 1,30 0,85 
Biotech 4,09 4,17 1,56 1,02 
Agbiotech 0,17 0,63 5,82 3,80 
Biopharma 0,81 1,20 2,27 1,48 
 
From the above table we are able to arrive. It is following the trend by investing the 
maximum in pharmaceuticals. However the rest of the world is also very hard at work 
producing knowledge that can be applied to the pharmaceuticals sector. Thus, we can 
identify an investment paradox in that even while India exhibits a comparative 
disadvantage with respect to the rest of the world in pharmaceuticals, this is 
where its investment is concentrated. Since the entire world is focussing on 
pharmaceuticals, the stakes are evidently higher in this field. Therefore, investing in 
pharmaceuticals makes sense in the long run. However, th  discrepancy between 
science production in agriculture and pharmaceuticals nnot be justified. More 
investment in agriculture is needed in keeping with India’s comparative advantage 
profile.  
 
Using the information on publications issuing from Gujarat and India, we have the 

















rest of India 
Agro 19,65 23,94 3,49 1,22 
Pharma 74,36 72,12 2,78 0,97 
Biotech 4,17 3,33 2,29 0,80 
Agbiotech 0,63 0,30 1,37 0,48 
Biopharma 1,20 0,30 0,72 0,25 
 
Again any investment in biotechnology goes against the recommendations of 
Ricardian theory as in all applications of biotechnology, Gujarat is at a distinct 
comparative disadvantage vis-à-vis the rest of the world. Again, if we take a long term 
view, then investment in biotechnology makes sense a  a means of bridging the 
“comparative advantage gap” between Gujarat and the rest of India. In this case, any 





3.2 Leadership position of regions  
In order to identify targets for the location of science parks in biotech, we studied the 
institutional affiliations of publications in the corpuses of scientific publications 
related to agriculture, pharmaceuticals, biotechnology. We did not distinguish 
between agbiotech and biopharma at this level since in any institution publishing on a 
multidisciplinary field is deemed to have knowledge in both.  
 
An examination revealed that there are 6 clusters of egions active in the creation of 
knowledge in biotechnology. They are New Delhi (with 12 leader labs), Bangalore 
(with 7 leader labs), Chandigarh (with 6 leader labs), Hyderabd (with 6 leader labs), 
Pune (with 6 leader labs), and Chennai (with 5 leader labs); clearly indicating at the 
all-India level, Gujarat is not among the leaders in biotechnology science production) 
(Coronini, Ramani and Venkatesh (2004)). However, if investment is to be 
undertaken in the creation of biotech parks, then an analysis of publications issuing 
from Gujarat would propose the following. 
 
Result 2: To maximize returns from science production in the fields of 
pharmaceuticals, agriculture and biotechnology, the “Science Parks” in Gujarat:  
 
• Ahmedabad and/or Baroda should be first choice to maxi ize short run 
returns; Anand and/or Vidyanagar should be second choice to maximize long 
run returns.  
 
• Ahmedabad should be the first choice for any science park to promote 
pharmaceuticals and biopharma  and it should include firms . 
 
• Ahmedabad should be the first choice for any science park to promote 
agbiotech along with agriculture and it should include firms. 
 
• Anand should be the first choice for any science park to promote pure 
agriculture and it should collaborate with Baroda . 
 
These results are self-evident from the following table.  
 
Table 3 
Number of laboratories in regions of Gujarat which have publications in 
agriculture, pharmaceuticals and biotechnology 
 
 Agriculture Pharmaceuticals Biotechnology Total 
Ahmedabad 10* 31** 3 F 44 
Anand 7* 3** 0 10 
Baroda or 
Vadodara 
3 F 14*** 3 F 20 
Bhavnagar 0 2 2 4 
Rajkot 1 2* 1 4 
Vidyanagar 2* 3 1 6 
 




*Pharmaceuticals: laboratories with authors who have more than 5 publications in 
pharmaceuticals.  
 
F indicates that a firm is among the science producers in the region.  
Table 3 presents the cities which have public labortories or private firms which are 
among the science producers in biotechnology or are among the top three regions in 
agriculture or pharmaceuticals science production. Clearly Ahmedabad and 
Baroda(now Vadodara) should be the candidate regions for any science park.  
 
In terms of number of labs involved in the publications on agriculture, the maximum 
number of laboratories involved is from Ahmedabad (10 labs), and then Anand (7 
labs). The scientists have a good network of Indian collaborators (28 joint 
publications) as well as with researchers from foreign institutes (24 joint 
publications). We find one non-public organization active in science production in 
Baroda, BAIF. 
 
A lot more is going on in pharmaceuticals as compared to the other fields. There are 
70 organizations that have been active in publications; with the two biggest regional 
clusters being Ahmedabad (with 31 organizations) and Baroda (with 13 organizations. 
Other cities have less than 5 organizations that are active in biotech science 
production. For the first time, we find a number of firms among the producers of 
science. There are 16 firms that are active in production of science related to 
pharmaceuticals. There are 10 hospitals that are also active. There is a good network 
of collaborations with Indian partners (84 collaborations) and a good network of 
collaborations with foreign partners (74 collaborations).  
 
In terms of the number of institutes active in creating knowledge in biotechnology, 
Baroda leads with 4 laboratories, followed by Bhavnagar and Ahmedabad with 2 
laboratories each. One firm is also present among the leading authors, namely Sun 
Pharma Advanced Research Centre. 
 
When we search for “cluster effects” or “synergy or spillover effects” due to the 
presence of star scientists, we are not able to detect any. Even in pharmaceuticals, 
where the weight of the publications is concentrated no positive “cluster” effect seems 
evident. For example publications from Ahmedabad do not dominate inspite of its 
weight in terms of number of organizations active in the production of science. It is 
Baroda which has a higher number of star scientists.  
 
A limitation of the above analysis is that with the available information it is not 
possible to rank the performance of these labs as science producers. 
 
3.3 Patent Analysis  
An examination of the patents issuing from Gujarat len itself to the following evident 
conclusions. 
 
Result 3: Analysis of patents issuing from Gujarat indicates that: 
• Transformation of science into new technology is greatest in pharmaceuticals; 
it is absent in agriculture and biotechnology (in terms of patents).  
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• While firms are active in science production there is no university laboratory 
that is active in new technology creation. 
• Any ambitious science park should try to include a unit for one or more of the 
following firms: Torrent Pharmaceuticals, Cadila, Cipla and Sun 
Pharmaceuticals, as well as public labs.  
There were no patents issuing from Gujarat corresponding to agriculture or 
biotechnology.  
 
In the field of pharmaceuticals, among the leading patentees from India listed in the 
USPTO as having more than 2 patents to their credit, we find the firms: Torrent 
Pharmaceuticals, Sun Pharmaceutical Industries Limited, Cadila Healthcare limited, 
Cadila pharmaceuticals ltd (Table A1 of Appendix). In the EPO database, among the 
leading patentees with more than 2 patent applications we again find Sun 
Pharmaceutical industries limited, Cadila healthcare limited, Cipla ltd, Cadila 
Pharmaceuticals ltd and Sun Pharmaceutical Industries l d. (Table A2 of Appendix). 
There are many patents from the public lab CSIR (Council for Scientific and 
Industrial Research) which has branches all over India including Gujarat. Since all 
patents are taken under the name of the CSIR without mention of which of the CSIR 
labs in India is responsible for the patent, it is not possible to gauge whether a CSIR 
lab in Gujarat has a patent.  
 
Thus, as the following table indicates, though we find irms being among the science 
producers along with universities and public labs, we do not find any university labs 
features as new technology producers.  
 
Table 4 
Leading Pharmaceutical firms in Gujarat 
 










Yes Yes Neuropsychiatry and 
cardiovascular drugs 
5.8% of revenue in 
R&D; half of it utilized 
for discovery  
Span Diagnostics, 
Surat 
No No Clinical laboratory reagents 
and diagnostic products 
with license from USFDA 
Technical tie-ups with 













with IISc, Bangalore; 
ICGEB, CBT, NII, 
Delhi 
Research facilities at 
Dholka, Ankaleswar 
and Bangalore  
Cipla, Ahmedabad No Yes Anti-AIDS drugs, animal 
healthcare, generic 
medicines 
Research in targeted 
therapy for 
autoimmune diseases 
Zydus Cadila, Yes No Pharmaceuticals, NMEs for clini al 
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Ahmedabad diagnostics, herbal 
products, skin care products 














4% of turnover 
committed to R&D 
Maps India, 
Ahmedabad 
No No Largest producer of 
industrial enzymes in India 
Identifying new 
microorganisms to 














subsidiary of Intas 
Pharmaceuticals) 
No No Neukine (rHu G-CSF) and 
Generic recombinant 
biopharmaceutical products 
Invested $10 million; 





No No Anaesthesia, Nutrition & 
Blood and Plasma 
products.  
R&D focused on new 
drug delivery systems 
Makson Pharma, 
Surendranagar 
No No Contract manufacturing for 
companies such as Boots 




No No Biologicals, contract 
research and recombinant 
products 




No No Pharmaceuticals Fermentation, 
Formulation, 
Process development 





No No Pharmaceuticals Basic, genomic, 
clinical research 
 
Source : Coronini, Ramani, Venkatesh (2004) Report on: “The Biotech Industry and its 
Development: What can Gujarat target?” 
 
There is however a fairly good record to technology transfer from public labs to 
private firms (see table A3 in Appendix). So there se ms to an institutional division of 
labour in this field with:  
 16 
• Universities being the primary producers of skilled abour that can be 
absorbed in public laboratories or private firms, and to a lesser extent new 
knowledge, without producing new technology; 
• Public labs conducting contract research for private firms and publishing 
rather than creating new technology or new firms.   
• Firms, especially the leaders, developing in-house R&D capacity so as to keep 
a foot in the scientific world through publications while creating new 
technology.  
 
The above implies that any science park in Gujarat must include both public labs and 
private firms as tenants because the division of labour is so engrained that to be 
innovation labs, there must be more collaboration between the two.  
4. Discussion of Results 
 
4.1. Gujarat’s plans for biotech parks 
A fact that is even more interesting than the spawning of S&T parks in India is that 
nobody really seems to know what is going on. Even the Allen Consulting Group 
(2005) confesses in its preface, “Plans for new parks re the subject of daily media 
announcements. Separating out what is actually being achieved from the numerous 
proposals has been a challenge.” We found no scientific articles on India or Gujarat 
on this subject but an internet search yielded fourmajor announcements that had been 
made in Gujrat between 2003 and 2006. 
(i) A biotech park “Gujarat Biotech Park at Vadodara (GBTP)” is being 
developed by the Gujarat Industrial Development Corporation (GIDC). GBTP 
is touted to be a hi-tech expandable project involving Rs. 540 million initial 
investments and spread over 40 hectares land area. P liminary infrastructure 
& technical facilities are already in place14. 
 
(ii)  Pharmaceutical Techno Park, a cluster development programme, in 
cooperation with UNIDO and the Quality Circle Networking for mutual 
quality upgrading is planned to be set up at Changodar near Ahmedabad15.   
 
 
(iii)A private company has also invested in the creation of a Biotech Park16. 
The Ahmedabad based company Ganesh Housing Corporation Ltd., an ISO 
9001-2000 has acquired a 32-acre land at Changodar near Ahmedabad on the 
Sarkhej–Bavla highway considered as the pharma corridor of Gujarat. It has 
proposed to develop an International Pharma & Biotech Park (IPBP).  This 
corridor already houses pharmaceutical companies lik  Intas Labs, Claris Life 
Sciences, Zydus Cadila and Makson Pharma. An investment of about Rs. 150 
million is reportedly being pumped into this project and the park is expected to 
house approximately 50 SME’s (small and medium entrepreneurs). 





Companies from outside of the State are also being invited to be tenants of the 
park. 
 
(iv) Plans for a Marine Biotech Park at Bhavnagar have also been revealed17.  
 
 
Comparing the investment targets with the results of the preceding analysis, we can 
infer the following conclusion.  
 
• Result 4: Investment targets for biotech parks in Gujarat diverge in some 
cases from those that can be inferred from an analysis of scientific 
publications and patent statistics.  
 
As may be recalled Ahmedabad and Baroda or Vadodara are the leaders in the fields 
of biotech and its applications. Therefore, it is asuring that the two big park 
investments are in Vadodara and Ahmedabad. However as table 5 summarizes, the 
comparative advantage of Gujarat lies in agriculture and Anand should be the first 
choice for any science park to promote pure agriculture. However, this is not present.  
 
There is also a danger of unnecessary competition between parks as two semi-private 
parks seek to place themselves in the same zone near Ahmedabad.  
 
A marine biotech lab has been announced in Bhavnagar, which already has two labs 
that have published in biotechnology journals, but it is not clear if this is the best 
choice for Gujarat to invest. 
 
Finally, there seems to be no search for appropriate public-private partnerships by 




A comparison of Investment targets and conclusions of analysis 
 
Announced Targets Inferences from analysis 
There are no parks targeting agbiotech Gujarat has a comparative advantage in 
agriculture 
Marine Biotech Park at Bhavnagar Though Bhavnagar hs 2 biotech labs it 
is not among the leaders. 
Gujarat Biotech Park at Vadodara Good choice; Vadodara or Baroda 
among leaders in biotech and its 
applications. What about composition? 
Pharmaceutical Techno Park and Biotech 
Park at Changodar near Ahmedabad 
 
Ahmedabad is among the leaders in 
pharmaceuticals but there are no public 
labs in Park. 
 




With the development of the information technology sectors and the biotechnology 
sectors, from the late 1980’s developing countries like India are spawning a high 
number of science and technology parks. However, thre seems to have been little 
enquiry as to the rationality of such investment. I the international economics and 
management literature, we could not find a single article devoted to the study of the 
evolution of S&T parks in India, marking this subject as an important area for 
research. 
 
In this article, we propose the use of patent application statistics and information on 
scientific publications as a tool for deciding where to invest in a science park and who 
the tenants ought to be.  
 
Using the tools proposed, we are able to recommend for Gujarat that : 
 
• There should be greater investment in science production related to agriculture 
as compared to pharmaceuticals in keeping with India’s and Gujarat’s 
comparative advantage profile.  
• There has to a greater generation of “cluster effects” or “spillover effect” in 
science production, perhaps through creating poles f excellence with star 
scientists.  
• Though Ahmedabad and Baroda are obvious choices for technoparks, they 
should be no duplication of efforts through focussing on the same sector 
namely pharmaceuticals.  
• Composition of tenants in a park has to be decided according to potential for 
synergy creation. 
• A science or technology park should focus on agriculture and agbiotech and a 
natural candidate region for this is Anand.  
 
Finally, our results are of course subject to the limitations of using patent application 
statistics and information on scientific publications. First, patent applications do not 
capture all of innovative activity and in a developing country like India and in sectors 
like agriculture, it may quite well miss out on the major innovation achievements. 
Second, Indian labs might have good access to international journals, so that the 
knowledge most specific, and perhaps useful to India is published in Indian journals, 
which are not referenced in international databases. In this case, exploitation of 
international databases may overlook local scientific production. Third, spatial 
investments like science and technology parks are also motivated by reasons other 
than the presence of scientific or technological competence. They might be the result 
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146 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 
30 DR. REDDY'S RESEARCH FOUNDATION 
29 HOECHST AKTIENGESELLSCHAFT 
21 RANBAXY LABORATORIES LIMITED 
19 DR. REDDY'S LABORATORIES LTD. 
15 WOCKHARDT LIMITED 
15 DABUR RESEARCH FOUNDATION 
14 TORRENT PHARMACEUTICALS LTD. 
14 PANACEA BIOTEC LIMITED 
8 NATIONAL INSTITUTE OF IMMUNOLOGY 
7 BOSTON UNIVERSITY 
6 SUN PHARMACEUTICAL INDUSTRIES LIMITED 
6 NATREON INC. 
5 MILLENNIUM PHARMACEUTICALS, INC. 
5 ORCHID CHEMICALS & PHARMACEUTICALS LIMITED 
5 DR. REDDY'S RESEARCH FOUNDATION & REDDY?CHEMINOR 
INC. 
5 LIPOSOME COMPANY, INC. 
4 KOPRAN RESEARCH LABORATORIES LIMITED 
4 RELIANCE LIFE SCIENCES PRIVATE LIMITED 
4 CIBA?GEIGY CORPORATION 
4 J. B. CHEMICALS & PHARMACEUTICALS LIMITED 
3 AVENTIS PHARMA DEUTSCHLAND GMBH 
3 UNITED STATES OF AMERICA, HEALTH & HUMAN SERVICES 
3 SABINSA CORPORATION 
3 BIOCON INDIA LIMITED 
3 REDDY CHEMINOR INC. 
3 USV LIMITED 
3 GENZYME CORPORATION 
3 IOWA INDIA INVESTMENTS COMPANY LIMITED 
3 CADILA HEALTHCARE LIMITED 
2 LUPIN LABORATORIES LIMITED 
2 UNIVERSITY OF CINCINNATI 
2 KANCOR FLAVOURS AND EXTRACTS LIMITED 
2 HEALTH RESEARCH, INCORPORATED 
2 AKTIEBOLAGET ASTRA 
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number. Assignee 
2 BIOPULPING INTERNATIONAL, INC. 
2 ORCHID HEALTH CARE 
2 UNIVERSITY OF CALIFORNIA, THE REGENTS OF 
2 DR. REDDY'S RESEARCH FOUNDATION AND REDDY?CHEMINOR, 
INC. 
2 U & I PHARMACEUTICALS LTD. 
2 TSAR HEALTH PRIVATE LTD. 
2 CADILA PHARMACEUTICALS, LTD. 
2 STRIDES INC. 
2 SAHAJANAD BIOTECH PRIVATE LIMITED 
2 CORNELL RESEARCH FOUNDATION INC. 
2 UNIVERSITY OF FLORIDA BOARD OF REGENTS 








53 RANBAXY LABORATORIES LIMITED  
14 SUN PHARMACEUTICAL INDUSTRIES LIMITED  
9 DR. REDDY'S LABORATORIES LTD. 
8 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 
8 NATCO PHARMA LIMITED  
8 DR. REDDY'S RESEARCH FOUNDATION 
7 CADILA HEALTHCARE LIMITED  
6 SUVEN LIFE SCIENCES LIMITED  
6 PANACEA BIOTEC LIMITED  
5 ORCHID CHEMICALS & PHARMACEUTICALS LTD  
5 SANKARANARAYANAN, ALANGUDI 
4 THEMIS LABORATORIES PRIVATE LIMITED  
4 DABUR RESEARCH FOUNDATION CORD, JANET, I. 
4 STRIDES ARCOLAB LIMITED 
4 KHAMAR, BAKULESH, MAFATLAL 
4 DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S 
LABORATORIES, INC.  
4 PATEL, DINESH, SHANTILAL KURANI, SHASHIKANT, 
PRABHUDAS 
3 MODI, RAJIV, INDRAVADAN  
3 ORCHID CHEMICALS & PHARMACEUTICALS LIMITED  
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number. Assignee 
3 CIPLA LIMITED WAIN, CHRISTOPHER, PAUL  
3 DR. REDDY'S LABORATORIES LIMITED  
3 CADILA PHARMACEUTICALS LIMITED  
3 SUN PHARMACEUTICAL INDUSTRIES LTD.  
3 J.B. CHEMICALS & PHARMACEUTICALS LTD. 
3 ASTRAZENECA AB  
3 ASTRA AKTIEBOLAG  
2 DR. REDDY'S RESEARCH FOUNDATION CORD, JANET, I.  
2 WOCKHARDT LIMITED  
2 GLENMARK PHARMACEUTICALS LIMITED MASS, CLIFFORD, J.  
2 SECRETARY, DEPARTMENT OF ATOMIC ENERGY  
2 BLUE CROSS LABORATORIES LIMITED  
2 DALMIA CENTRE FOR RESEARCH AND DEVELOPMENT  
2 NICHOLAS PIRAMAL INDIA LIMITED  
2 UNIVERSITY OF MADRAS  
2 INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND 
BIOTECHNOLOGY  
2 VYAS, SHARAD, KUMAR 




Technology Transfer in Gujarat 
 
 A Leprosy immunomodulator has been transferred from the National 
Institute of Immunology to Cadila Laboratories, Ahmedabad. 
 A Leishmaniasis detection kit has been transferred from CDRI, 
Lucknow to Span Diagnostics Ltd. Surat. 
 Blood grouping monoclonals has been transferred from NII, New 
Delhi to Cadila Laboratories, Ahmedabad 
 Mass production of Biopesticides from Aspergillus niger has been 
transferred from IARI, New Delhi to Cadila Laboratories, Ahmedabad 
 Amaranthus protein gene for nutritionally enriched animal feed has 
been transferred from NCPGR, New Delhi to Cadila Labor tories, 
Ahmedabad 
 The IgM Mac ELISA for the detection of Dengue has been transferred 
from National Institute of Virology, Pune to Zydus Cadila HealthCare, 
Ahmedabad 
 The IgM Mac ELISA for the detection of Japanese Encephalitis has 
been transferred from National Institute of Virology, Pune to Zydus 
Cadila HealthCare, Ahmedabad 
 The IgM Mac ELISA for the detection of West Nile virus has been 
transferred from National Institute of Virology, Pune to Zydus Cadila 
HealthCare, Ahmedabad 
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 Urine based system (ELISA) for the detection of Four Reproductive 
Hormones has been transferred from Institute for Research in 
Reproduction, Mumbai to Zydus Cadila HealthCare, Ahmedabad 
 A technology utilizing Yarrowia lipolytica expressing Hepatitis B 
surface and pre S genes (yielding high level of proteins / single step 
purification) has been transferred from the M. S. University, Baroda to 
Biological Evans Ltd., Hyderabad 
 A technology for expressing hCG using Pichia pastoris system has 
been transferred from the Indian Institute of Sciene, Bangalore to 
Cadila Pharamaceuticals Ltd., Ahmedabad 
 Plant Tissue Culture technology has been transferred f om TERI, New 
Delhi to Cadila Pharmaceuticals Ltd., Ahmedabad 
 Plant Tissue Culture technology has been transferred f om NCL, Pune 
to Cadila Pharmaceuticals Ltd., Ahmedabad 
 
Compiled using Internet sources of information 
o http://www.ey.com/global/download.nsf/India/ProgressionsPharma
2004/$file/ProgressionsPharma2004.pdf 














o http://www.cadilapharma.com/  
o http://www.cipla.com/ 
 
